Pharmaceutical companies are constantly adapting and evolving their systems to keep up with new regulatory requirements. But modernization isn’t always easy, and it must be done without disrupting quality, efficiency, and most importantly, compliance. In a highly regulated industry like pharma, it’s essential to carefully plan each change.  There is a delicate balance between enhancing […]

As health authorities around the world move steadily toward structured labeling standards like electronic Product Information (ePI), Pharma Ledger, and Structured Product Monograph (SPM), mid-to-large-sized pharmaceutical companies are asking a critical question: How do we support global requirements without overextending our internal teams or making irreversible investments? For many, the answer is to partner with […]

Pharmaceutical organizations, whether global giants or mid-sized companies, are facing a regulatory wave. With the Jordan Food and Drug Administration (JFDA) mandating the submission of electronic product information (ePI) in the Fast Healthcare Interoperability Resources (FHIR) format, the European Medicine Agency (EMA) wrapping up its successful FHIR pilot program, and a growing number of countries […]

In today’s increasingly complex regulatory landscape, pharmaceutical companies face mounting pressure to streamline their global labeling operations. Before diving headfirst into a full-scale global labeling transformation, a targeted pilot engagement offers a strategic and risk-mitigated approach. A well-designed pilot not only illuminates current-state gaps across document management, content structuring, and publishing outputs but also validates […]

 Across the pharmaceutical industry, many regulatory agencies are pushing for a transition to Electronic Product Information (ePI). But what exactly is ePI, and why is this transition happening? Electronic Product Information, or ePI, refers to a digital version of product labeling that patients and healthcare professionals rely on every day. Things like dosage, administration, side […]

Bringing a pharmaceutical product to market requires navigating a complex, evolving regulatory landscape. One critical area in this journey is Pharmaceutical Quality Chemistry, Manufacturing, and Controls (PQ CMC): a cornerstone of health authority submissions that’s often manual, document-centric, and labor-intensive. Here’s what you need to know. PQ CMC isn’t just a box to check; it’s […]

Just one week after directing agencies to accelerate American-based pharmaceutical manufacturing, President Donald Trump signed another executive order (EO) on May 12, 2025. This EO focused squarely on reducing the cost of prescription drugs for American patients and taxpayers. The two orders reflect a broader shift in U.S. pharmaceutical policy: a movement toward increasing domestic […]

How Shifting U.S. Policy Impacts Pharmaceutical Strategy On May 5, 2025, President Donald Trump signed an executive order, Promoting American-Made Prescription Drugs. While the policy is primarily focused on bolstering U.S.-based pharmaceutical manufacturing, its implications reach far beyond domestic borders. Pharmaceutical leaders around the globe, especially those managing complex, multi-country supply chains, should take note. […]

Tariffs are affecting many industries in 2025, and pharmaceuticals are not being spared. Although new U.S. tariffs on Chinese imports were briefly enacted this year, they were quickly placed on hold. This pause has not eliminated uncertainty. Instead, it has added to the broader sense of economic hesitation, especially in industries like pharmaceuticals that depend […]

In the increasingly complex world of global labeling, tracking changes across labeling content is more than a best practice—it’s a regulatory necessity. Health authorities around the globe are demanding more detailed accountability, documentation, and traceability of every change made throughout the product lifecycle. Staying compliant is a major challenge for many companies, especially those with […]